A catheter that fractures inside the body can support a product liability claim, and the current benchmark is a $40 million compensatory verdict — not a settlement. One Phoenix federal jury reached that figure in September 2026 in the Bard implanted port catheter litigation, but the defense has already moved for a new trial, so the number is not final and no global settlement exists. That gap between a headline verdict and money in hand is the whole subject of this page. A fracture claim moves through four stages — proving the device failed, proving the failure hurt you, surviving post-trial motions, and surviving a preemption appeal — and each stage can cut the value sharply.
Official resources:
- Read the original report from NIH — Use this primary source to review the complete report.
- Read the original report from FDA — Use this primary source to review the complete report.
Table of Contents
- What a catheter fracture claim actually alleges
- Where the Bard port litigation stands
- Why $40 million is not a case value
- The damages problem nobody expects — a clean retrieval
- Preemption is the appellate issue that decides everything
- What a claimant can do now
- Frequently Asked Questions
What a catheter fracture claim actually alleges
A catheter is a thin tube placed in a blood vessel to deliver drugs, fluids or contrast dye. An implanted port is a version left in place for months or years, with a reservoir under the skin feeding a catheter into a large vein. A fracture means the tube cracks or separates; the loose piece can travel with the bloodstream, which doctors call migration or embolization. The claims are product liability theories, not medical malpractice.
Plaintiffs typically allege design defect — the device was built in a way that made cracking foreseeable — and failure to warn, meaning the manufacturer did not tell doctors and patients what it knew about the failure rate. Some also allege manufacturing defect, where a specific production run departed from the approved design. Regulators have documented this failure mode, which matters because it removes the argument that fracture is a freak event. The FDA labeled Cook Medical's removal of Beacon Tip 5.0 Fr angiographic catheters a Class I recall, its most serious category, over tip separation leading to fragmentation and embolization, with three serious injuries reported and the cause traced to a failure in process change control. A separate FDA Class I action on Bard PowerPICC catheters describes material-fatigue leaks appearing as transverse or circumferential cracks in the catheter body, with embolism and infection among the listed risks and clinicians told to stop infusing if they suspect a defect.
Where the Bard port litigation stands
Most federal fracture claims sit in one place. MDL 3081, the Bard implanted port catheter litigation, is centralized in the District of Arizona before Judge David G. Campbell, and Settlement Record reports roughly 4,140 pending actions as of the JPML's October 1, 2026 count, up from 3,734 a month earlier. Alleged injuries include fracture, migration, blood clots and infection. An MDL consolidates pretrial work; it does not merge the cases into one claim, and each plaintiff still has to prove their own injury.
The fracture bellwether produced the big number. According to an October 28, 2026 GlobeNewswire release, a Phoenix federal jury awarded $40 million in compensatory damages on September 4, 2026 on design-defect and failure-to-warn theories, with judgment entered September 10. The jury declined to award punitive damages and declined to find fraudulent concealment — a signal that it accepted the defect case but not the bad-faith case. Read the full bellwether record, not one result. MDL Update's tracker notes that a May 2026 Phoenix trial ended in a defense verdict and an Arizona jury again found for Bard in the third bellwether in early November 2026, with no global Bard PowerPort settlement announced. Two defense wins against one large plaintiff verdict is a mixed scoreboard, and mixed scoreboards push settlement values down rather than up.
Why $40 million is not a case value
A verdict is a ceiling for one plaintiff, not a price list. Bard moved on October 8, 2026 for a new trial, arguing the award was "manifestly excessive" and that plaintiff's counsel improperly exploited expert-compensation evidence — the trial testimony about how much the experts were paid. That motion has to be resolved before any appeal can proceed.
The outcome most people overlook is remittitur. A judge who finds a verdict excessive can cut it without ordering a new trial, leaving the liability finding intact and the dollars reduced. The plaintiff's usual choice is to accept the reduced figure or retry the case.
- A post-trial motion can wipe out the verdict entirely and send the case back to a jury.
- Remittitur can keep the win and shrink the award.
- An appeal after that adds a year or more before anything is paid.
- Bellwethers are chosen to be strong, so they are not average cases.
The damages problem nobody expects — a clean retrieval
The strength of a fracture claim depends heavily on what happened after the break. Most fragments come out without surgery. A single-center series retrieved 46 of 47 dislodged port catheters by transcatheter methods, a 97.8% success rate, with 21.3% needing a repeat attempt, and a pediatric series of 26 reported 92.3% success using a femoral snare with no complications. That clinical good news is legal bad news for valuation.
An uneventful retrieval under local anesthetic produces a short hospital stay, modest bills, and limited provable harm. Defense counsel will use exactly those figures to argue the injury was a procedure, not a catastrophe. The cases that carry real value are the ones with documented downstream damage: an open-chest or vascular surgery because the fragment could not be snared, a clot or embolism, bloodstream infection, cardiac arrhythmia from a fragment lodged in the heart, or an interruption in chemotherapy while the port was replaced. Keep the imaging, the retrieval report, the device identifiers and the explanted hardware itself if the hospital will release it.
Preemption is the appellate issue that decides everything
The defense with the most power on appeal is federal preemption. In *Riegel v. Medtronic*, 552 U.S. 312, decided February 20, 2008 by an 8-1 vote with Justice Scalia writing, the Supreme Court held that the Medical Device Amendments bar state common-law design and labeling claims against devices that went through FDA premarket approval.
The case itself arose from a ruptured Medtronic angioplasty balloon catheter. The practical effect is a sorting rule by regulatory pathway. Premarket approval, the FDA's most rigorous route, brings strong preemption and leaves room mainly for "parallel" claims — allegations that the maker deviated from its own FDA-approved specifications or manufacturing requirements. Devices cleared through the lighter 510(k) pathway, which covers most implanted ports and PICC lines, do not get that shield. This is why a process-change-control failure of the kind the FDA cited in the Cook recall is worth more than a general design argument: a deviation from approved specifications survives preemption where a pure design claim may not.
What a claimant can do now
Non-Bard claimants face a longer road still. MDL Update reports that AngioDynamics port catheter MDL 3125 has no announced settlements and first trials not expected until early 2028, which means a claimant filing there today is years from any trial-driven valuation.
- Identify the exact device — manufacturer, brand, catalog and lot number. They appear on the implant record or device card, and they decide which litigation, if any, you belong in.
- Request the full imaging set and the retrieval or surgical report, not just the discharge summary.
- Check the clock. Statutes of limitations run from injury or discovery depending on the state, and a fragment found years later raises a discovery-rule fight.
- Ask any lawyer directly whether your device went through premarket approval or 510(k) clearance, and what that means for preemption in your case.
- Expect a wait rather than a near-term check. There is no Bard global settlement, and the lead verdict is still inside post-trial motions.
Frequently Asked Questions
Does a fractured catheter automatically mean I have a case?
No. You need a device with a documented failure mode, proof the fracture caused harm beyond a routine retrieval, and a claim that survives federal preemption for that device's approval pathway.
Is this a malpractice claim against my doctor or hospital?
Fracture claims are usually brought against the manufacturer as product liability. A malpractice claim is a separate theory, aimed at how the device was placed, used or monitored.
What is a bellwether trial, and why does it affect my case?
It is a test case tried early so both sides learn what juries do with the evidence. Results set negotiation expectations across the MDL, which is why a defense verdict in one bellwether can lower everyone's leverage.
Can the $40 million verdict be reduced without a new trial?
Yes. A judge who finds an award excessive can order remittitur, keeping the liability finding and cutting the damages figure; the plaintiff then accepts the lower sum or retries the case.